Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Gigacloud Technology Inc (GCT) vs Novo Nordisk A/S (NVO) Price & Performance

Gigacloud Technology IncTrade
Novo Nordisk A/STrade

Price performance (Past 24H)

Key statistics

Gigacloud Technology Inc vs Novo Nordisk A/S — how do they compare? Gigacloud Technology Inc trades at $52.01 (market cap $1.84B), while Novo Nordisk A/S trades at $46.28 (market cap $207.85B). The key difference: Novo Nordisk A/S is far larger — about 113× Gigacloud Technology Inc's market cap, and Novo Nordisk A/S pays a 3.81% dividend while Gigacloud Technology Inc pays none. Which is the better fit depends on your goals.

GCTNVO
Market Cap
$1.84B$207.85B
Sector
TechnologyHealth
52-Week High
$53.25$63.98
52-Week Low
$25.44$35.29
Enterprise Value
$1.97B$222.55B
Dividend Yield
3.81%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Gigacloud Technology Inc

GigaCloud Technology (GCT) trades at $51.68, up 0.06% on the day, with a bullish technical outlook supported by moving averages and strong support at $50. The company reported Q2 2026 EPS of $1.16, beating estimates, and maintains a net income margin of 10.65%. Revenue growth is projected to rise from $1.29B in 2025 to $1.5B in 2026, while analyst sentiment is positive with a 66.7% buy rating.

The stock presents a compelling opportunity due to consistent earnings beats, robust profitability metrics like a 32.34% ROE, and attractive valuation with a P/E of 12.25. Key risks include reliance on B2B furniture logistics, competitive pressures, and potential margin compression from higher costs. Institutional confidence is bolstered by a $120M buyback program announced in Q2 2026.

Novo Nordisk A/S

Novo Nordisk (NVO) trades at $46.465, down 2.65% today, with a neutral technical signal. The stock shows strong fundamentals, including a P/E of 11.62, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights competitive pressures from Eli Lilly and mixed investor reactions to Q2 2026 results, despite an upwardly revised full-year outlook.

Outlook remains positive due to robust GLP-1 drug demand and profitability, but risks include pricing pressure and competition. Analysts are predominantly bullish (57.9% buy ratings), supporting a favorable long-term view despite near-term volatility.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Gigacloud Technology Inc

Gigacloud Technology operates a global B2B e-commerce marketplace for large-parcel goods. It provides a comprehensive solution for furniture manufacturers and retailers with integrated logistics and fulfillment.

Read more on GCT

About Novo Nordisk A/S

With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Read more on NVO